Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Retained Earnings (2019 - 2025)

Eton Pharmaceuticals (ETON) has disclosed Retained Earnings for 7 consecutive years, with -$112.5 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 4.26% to -$112.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$112.5 million through Dec 2025, down 4.26% year-over-year, with the annual reading at -$112.5 million for FY2025, 4.26% down from the prior year.
  • Retained Earnings hit -$112.5 million in Q4 2025 for Eton Pharmaceuticals, up from -$114.0 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$87.0 million in Q1 2021 to a low of -$114.0 million in Q3 2025.
  • Historically, Retained Earnings has averaged -$103.1 million across 5 years, with a median of -$104.1 million in 2022.
  • Biggest five-year swings in Retained Earnings: dropped 18.85% in 2021 and later increased 2.15% in 2023.
  • Year by year, Retained Earnings stood at -$94.1 million in 2021, then fell by 9.59% to -$103.1 million in 2022, then dropped by 0.91% to -$104.1 million in 2023, then dropped by 3.67% to -$107.9 million in 2024, then fell by 4.26% to -$112.5 million in 2025.
  • Business Quant data shows Retained Earnings for ETON at -$112.5 million in Q4 2025, -$114.0 million in Q3 2025, and -$112.0 million in Q2 2025.